---
document_datetime: 2026-01-16 13:06:17
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/irbesartan-hydrochlorothiazide-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: irbesartan-hydrochlorothiazide-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.7554808
conversion_datetime: 2026-01-17 13:09:13.530062
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Irbesartan Hydrochlorothiazide Zentiva

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 16/01/2026                          |                                             | SmPC,                            |           |

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000314724                     | PRODUCTS - C.I.z Change(s) in the SmPC, labelling or package leaflet of human medicinal products in order to adapt to a recommendation of a competent authority , e.g. a Core SmPC, following the assessment of an Urgent Safety Restriction etc. Implementation of wording agreed by the competent authority that require additional minor assessment, e.g. translations are not yet agreed upon. - Accepted C.I.z - to update section 5.3 of Annex I (SmPC) following assessment of the same change for the reference product CoAprovel (EMEA/H/C/000222 - EMA/VR/0000265130), in line with the EPAR published on 25 September 2025. Additionally, the MAH took the opportunity to introduce minor editorial changes throughout Annex I (SmPC) to align it with the reference product. Furthermore, editorial changes in HU, LV and SK national translations have been performed to bring   |            |     | Labelling and PL   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------|
| Variation type IB / EMA/VR/0000308338 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2 Change in test procedure for active substance or starting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15/01/2026 | N/A |                    |

<div style=\"page-break-after: always\"></div>

|                                          | material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted                                                                          |            |     |             |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IA_IN / EMA/VR/0000313373 | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.3 New certificate from a new manufacturer (replacement or addition) - Accepted                                                                                                                                 | 17/11/2025 | N/A |             |
| Variation type IB / EMA/VR/0000268656    | B.II.a.3 Changes in the composition (excipients) of the finished product - B.II.a.3.z Other changes - Accepted                                                                                                                                                                                                             | 17/06/2025 |     | SmPC and PL |
| Variation type IA_IN / EMA/VR/0000247275 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of wording agreed by the competent authority that do not require any further assessment - Accepted | 29/01/2025 |     | SmPC and PL |
| Variation type IB / EMA/VR/0000238897    | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated                                                                                                                                                                                                      | 18/12/2024 | N/A |             |

<div style=\"page-break-after: always\"></div>

|                                       | certificate from an already approved manufacturer - Accepted                                                                                                                                                                                                                                                                      |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000241687 | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted                                                                                                                                                | 16/12/2024 | N/A |
| Variation type IA / EMA/VR/0000232109 | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted | 03/11/2024 | N/A |
| Variation type IA / EMA/VR/0000221503 | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted                                                                                                                                                | 16/07/2024 | N/A |